drugset / Trial / NCT03385096

Summary

The purpose of this study is to evaluate the safety and efficacy of Melphalan and BUCY+VP-16 myeloablative conditioning regimens in multiple myeloma undergoing autologous hematopoietic stem cell transplantation.

Timeline

Start
2018-01-02
Primary completion
2020-12
Completion
2021-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Busulfan Small molecule 3.2 mg/kg
Subject Cyclophosphamide Other / unclassified 60 mg/kg
Subject Etoposide Small molecule 10 mg/kg
Comparator Melphalan Small molecule 200 mg/m2